MondegarAI
Logos Global Management LP

Q1 2025 · 13F-HR

Logos Global Management LPholdings as filed

Filed 2025-05-15 · accession 0001172661-25-002012

$562.5M
Reported value
39
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
45166A102IDYAIDEAYA BIOSCIENCES INC$57.3M10.2%3,500,000CommonSOLE
76155X100RVMDREVOLUTION MEDICINES INC$56.6M10.1%1,600,000CommonSOLE
00973Y108AKROAKERO THERAPEUTICS INC$48.6M8.64%1,200,000CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$44.5M7.92%1,650,000CommonSOLE
670703107NUVLNUVALENT INC$35.5M6.30%500,000CommonSOLE
881624209TEVATEVA PHARMACEUTICAL INDS LTD$26.1M4.64%1,700,000CommonSOLE
98420N105XENEXENON PHARMACEUTICALS INC$21.8M3.88%650,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$20.4M3.62%2,000,000CommonSOLE
254604101IRONDISC MEDICINE INC$19.6M3.48%394,342CommonSOLE
09075V102BNTXBIONTECH SE$18.2M3.24%200,000CommonSOLE
282559103ETNBGBP89BIO INC$18.2M3.23%2,500,000CommonSOLE
834203309SLNOSOLENO THERAPEUTICS INC$17.9M3.18%250,000CommonSOLE
29479A108ERASERASCA INC$17.8M3.17%13,000,000CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$16.9M3.00%2,300,000CommonSOLE
25056L103DSGNDESIGN THERAPEUTICS INC$16.3M2.89%4,217,627CommonSOLE
61559X104MLTXMOONLAKE IMMUNOTHERAPEUTICS$13.7M2.43%350,000CommonSOLE
374163103GERNGERON CORP$12.7M2.26%8,000,000CommonSOLE
68062P106OLMAOLEMA PHARMACEUTICALS INC$12.1M2.14%3,208,875CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS IN$11.7M2.09%350,000CommonSOLE
05370A108RNAGBPAVIDITY BIOSCIENCES INC$10.3M1.84%350,000CommonSOLE
578784100MAZEMAZE THERAPEUTICS INC$10.3M1.83%936,914CommonSOLE
03589W102ANNXANNEXON INC$7.7M1.37%4,000,000CommonSOLE
86366E106GPCRSTRUCTURE THERAPEUTICS INC$7.4M1.31%425,000CommonSOLE
20451W101CMPSCOMPASS PATHWAYS PLC$5.7M1.02%2,000,000CommonSOLE
26818M108DYNDYNE THERAPEUTICS INC$5.2M0.93%500,000CommonSOLE
29337E102ELVNENLIVEN THERAPEUTICS INC$4.7M0.84%240,000CommonSOLE
45258J102IMVTIMMUNOVANT INC$4.7M0.84%275,000CommonSOLE
008064107AEROVATE THERAPEUTICS INC$3.5M0.62%1,400,000CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$3.4M0.60%2,222,222CommonSOLE
90466Y103UNICYCIVE THERAPEUTICS INC$2.9M0.52%5,078,927CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$2.7M0.47%424,715CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$2.7M0.47%500,000CommonSOLE
75383L102RAPPRAPPORT THERAPEUTICS INC$2.1M0.37%208,910CommonSOLE
38000Q102GLYCEURGLYCOMIMETICS INC$1.1M0.20%5,400,000CommonSOLE
81734D104SEPNSEPTERNA INC$777,0300.14%134,202CommonSOLE
01671P100ALLKGUSDALLAKOS INC$660,0400.12%2,900,000CommonSOLE
04317A107ARTVARTIVA BIOTHERAPEUTICS INC$435,2670.08%145,089CommonSOLE
83422E204SLDBSOLID BIOSCIENCES INC$370,0000.07%100,000CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$15,9200.00%66,666CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.